Arcutis Biotherapeutics' Application for Seborrheic Dermatitis Treatment Gets FDA Approval
December 15 2023 - 4:49PM
Dow Jones News
By Denny Jacob
Arcutis Biotherapeutics' new drug application for zoryve topical
foam as a treatment for seborrheic dermatitis received approval
from the Food and Drug Administration.
The early commercial-stage company said the zoryve's approval is
for the treatment of seborrheic dermatitis in people ages nine
years and older.
Arcutis intends to make zoryve foam widely available through
wholesaler and dermatology pharmacy channels as a new treatment
option by the end of January.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 15, 2023 17:34 ET (22:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2024 to May 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From May 2023 to May 2024
